Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients

A. Canessa, V. Del Bono, P. De Leo, N. Piersantelli, A. Terragna

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Twenty-four consecutive HIV-positive patients affected by Toxoplasma gondii encephalitis received trimethoprim-sulfamethoxazole (cotrimoxazole) as acute-phase treatment. Two dosage regimens of cotrimoxazole were used: 40 mg/kg/day (12 patients) or 120 mg/kg/day (12 patients) of total compound (trimethoprim plus sulfamethoxazole). Clinical and radiological responses to treatment were evaluated, and the product-limit method for survival data analysis was used. Eighteen of 24 patients showed both a clinical and radiological response (75 % response rate). There were no differences in response rates between patients receiving the two dosage regimens of cotrimoxazole. Adverse reaction consisted of leukopenia (two cases) and skin rash (three cases) which led to the discontinuation of the drug in one case. These results suggest that a randomized, controlled clinical trial should be carried out comparing cotrimoxazole versus sulfadiazine-pyrimethamine in AIDS patients with Toxoplasma gondii encephalitis.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 1992

Fingerprint

Sulfamethoxazole Drug Combination Trimethoprim
Toxoplasma
Encephalitis
Acquired Immunodeficiency Syndrome
Therapeutics
Sulfadiazine
Pyrimethamine
Leukopenia
Kaplan-Meier Estimate
Survival Analysis
Exanthema
Randomized Controlled Trials
HIV
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this

Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients. / Canessa, A.; Del Bono, V.; De Leo, P.; Piersantelli, N.; Terragna, A.

In: European Journal of Clinical Microbiology and Infectious Diseases, Vol. 11, No. 2, 02.1992, p. 125-130.

Research output: Contribution to journalArticle

Canessa, A. ; Del Bono, V. ; De Leo, P. ; Piersantelli, N. ; Terragna, A. / Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients. In: European Journal of Clinical Microbiology and Infectious Diseases. 1992 ; Vol. 11, No. 2. pp. 125-130.
@article{03e118e86e074e0c8ff7e47ba8751827,
title = "Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients",
abstract = "Twenty-four consecutive HIV-positive patients affected by Toxoplasma gondii encephalitis received trimethoprim-sulfamethoxazole (cotrimoxazole) as acute-phase treatment. Two dosage regimens of cotrimoxazole were used: 40 mg/kg/day (12 patients) or 120 mg/kg/day (12 patients) of total compound (trimethoprim plus sulfamethoxazole). Clinical and radiological responses to treatment were evaluated, and the product-limit method for survival data analysis was used. Eighteen of 24 patients showed both a clinical and radiological response (75 {\%} response rate). There were no differences in response rates between patients receiving the two dosage regimens of cotrimoxazole. Adverse reaction consisted of leukopenia (two cases) and skin rash (three cases) which led to the discontinuation of the drug in one case. These results suggest that a randomized, controlled clinical trial should be carried out comparing cotrimoxazole versus sulfadiazine-pyrimethamine in AIDS patients with Toxoplasma gondii encephalitis.",
author = "A. Canessa and {Del Bono}, V. and {De Leo}, P. and N. Piersantelli and A. Terragna",
year = "1992",
month = "2",
doi = "10.1007/BF01967063",
language = "English",
volume = "11",
pages = "125--130",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Vieweg",
number = "2",

}

TY - JOUR

T1 - Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients

AU - Canessa, A.

AU - Del Bono, V.

AU - De Leo, P.

AU - Piersantelli, N.

AU - Terragna, A.

PY - 1992/2

Y1 - 1992/2

N2 - Twenty-four consecutive HIV-positive patients affected by Toxoplasma gondii encephalitis received trimethoprim-sulfamethoxazole (cotrimoxazole) as acute-phase treatment. Two dosage regimens of cotrimoxazole were used: 40 mg/kg/day (12 patients) or 120 mg/kg/day (12 patients) of total compound (trimethoprim plus sulfamethoxazole). Clinical and radiological responses to treatment were evaluated, and the product-limit method for survival data analysis was used. Eighteen of 24 patients showed both a clinical and radiological response (75 % response rate). There were no differences in response rates between patients receiving the two dosage regimens of cotrimoxazole. Adverse reaction consisted of leukopenia (two cases) and skin rash (three cases) which led to the discontinuation of the drug in one case. These results suggest that a randomized, controlled clinical trial should be carried out comparing cotrimoxazole versus sulfadiazine-pyrimethamine in AIDS patients with Toxoplasma gondii encephalitis.

AB - Twenty-four consecutive HIV-positive patients affected by Toxoplasma gondii encephalitis received trimethoprim-sulfamethoxazole (cotrimoxazole) as acute-phase treatment. Two dosage regimens of cotrimoxazole were used: 40 mg/kg/day (12 patients) or 120 mg/kg/day (12 patients) of total compound (trimethoprim plus sulfamethoxazole). Clinical and radiological responses to treatment were evaluated, and the product-limit method for survival data analysis was used. Eighteen of 24 patients showed both a clinical and radiological response (75 % response rate). There were no differences in response rates between patients receiving the two dosage regimens of cotrimoxazole. Adverse reaction consisted of leukopenia (two cases) and skin rash (three cases) which led to the discontinuation of the drug in one case. These results suggest that a randomized, controlled clinical trial should be carried out comparing cotrimoxazole versus sulfadiazine-pyrimethamine in AIDS patients with Toxoplasma gondii encephalitis.

UR - http://www.scopus.com/inward/record.url?scp=0026562232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026562232&partnerID=8YFLogxK

U2 - 10.1007/BF01967063

DO - 10.1007/BF01967063

M3 - Article

VL - 11

SP - 125

EP - 130

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 2

ER -